RxDoctor Payments Data

Richard Saint, MD

Urology · Tulsa, OKNPI 1851313373

Payments from drug & device makers

$5,264in general payments, 2019–2025

Across 169 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Sumitomo Pharma America, Inc.$333
  • Astellas Pharma US Inc$306
  • Teleflex LLC$300
  • AbbVie$283
  • Pfizer$263
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$1,51729%
  • Food & beverage$3,60168%
  • Education$1453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,264 in reported general payments places this provider in the 55th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$176,593
Medicare patients
497
Services billed
1,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron74$45,437
MyrbetriqMirabegron38$29,585
Tamsulosin Hcl189$2,770
Tolterodine Tartrate ErTolterodine Tartrate29$2,338
Estradiol39$1,969
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst48$1,365
Testosterone Cypionate28$753
Trospium Chloride23$621
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen107$528
Levofloxacin102$527
Finasteride39$463
Cephalexin36$329
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$227
Tramadol Hcl75$165
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$333$45,43774 claims
Astellas Pharma US IncMyrbetriq$306$29,58538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 145 urology providers in Oklahoma.

Other urology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →